Oncology Drugmakers & Research Tools

Cancer treatment creates a distinct investment chain spanning established oncology franchises, targeted therapies and the laboratory tools used to develop them. This basket emphasizes commercial drugmakers rather than speculative discovery platforms, with research infrastructure providing a complementary business model. Upcoming earnings from several core holdings offer a near-term test of product demand and pipeline execution; clinical setbacks and drug-pricing pressure remain material risks. Launch basket (equal weight): MRK, ABBV, AMGN, LLY, TMO, REGN, INCY, BMY Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.